Mayne Pharma Group Limited (MYX.AX)
AUD 6.98
(-0.29%)
AUD 6.98
(-0.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -116.92 Million AUD | 39.67% |
| 2023 | -193.8 Million AUD | -81.42% |
| 2022 | -78.88 Million AUD | -195.9% |
| 2021 | -182.39 Million AUD | -3.98% |
| 2020 | -34.03 Million AUD | -41.43% |
| 2019 | -241.15 Million AUD | 5.7% |
| 2018 | -71.07 Million AUD | -40.28% |
| 2017 | 201.12 Million AUD | 154.86% |
| 2016 | 73.7 Million AUD | 150.5% |
| 2015 | 31.68 Million AUD | -27.33% |
| 2014 | 42.23 Million AUD | 369.33% |
| 2013 | 8.93 Million AUD | -28.85% |
| 2012 | 13.36 Million AUD | 48.33% |
| 2011 | 8.05 Million AUD | 15.18% |
| 2010 | 8.69 Million AUD | 279.46% |
| 2009 | -4.09 Million AUD | -18.78% |
| 2008 | -3.45 Million AUD | -90.4% |
| 2007 | -1.81 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | 23.36 Million AUD | 0.0% |
| 2024 Q2 | -2.95 Million AUD | 0.0% |
| 2024 FY | - AUD | 92.25% |
| 2023 FY | - AUD | -81.42% |
| 2023 Q2 | -93.09 Million AUD | 0.0% |
| 2023 Q4 | -27.91 Million AUD | 0.0% |
| 2022 Q2 | 17.43 Million AUD | 0.0% |
| 2022 FY | - AUD | -195.9% |
| 2022 Q4 | 1.28 Million AUD | 0.0% |
| 2021 Q2 | 38.61 Million AUD | 0.0% |
| 2021 Q4 | 30.93 Million AUD | 0.0% |
| 2021 FY | - AUD | -3.98% |
| 2020 FY | - AUD | -41.43% |
| 2020 Q2 | 34.35 Million AUD | 0.0% |
| 2020 Q4 | 38.08 Million AUD | 0.0% |
| 2019 Q4 | 44.95 Million AUD | 0.0% |
| 2019 FY | - AUD | 5.7% |
| 2019 Q2 | 68.07 Million AUD | 0.0% |
| 2018 Q2 | 35.25 Million AUD | 0.0% |
| 2018 FY | - AUD | -40.28% |
| 2018 Q4 | 105.82 Million AUD | 0.0% |
| 2017 Q2 | 101.76 Million AUD | 0.0% |
| 2017 Q4 | 85.67 Million AUD | 0.0% |
| 2017 FY | - AUD | 154.86% |
| 2016 FY | - AUD | 150.5% |
| 2016 Q4 | 34.24 Million AUD | 0.0% |
| 2016 Q2 | 31.78 Million AUD | 0.0% |
| 2015 Q4 | 16.61 Million AUD | 0.0% |
| 2015 Q2 | 11.87 Million AUD | 0.0% |
| 2015 FY | - AUD | -27.33% |
| 2014 Q2 | 18.61 Million AUD | 0.0% |
| 2014 FY | - AUD | 369.33% |
| 2014 Q4 | 21.84 Million AUD | 0.0% |
| 2013 Q4 | 13.01 Million AUD | 882.31% |
| 2013 Q3 | 1.32 Million AUD | -77.88% |
| 2013 Q2 | 5.99 Million AUD | 0.0% |
| 2013 FY | - AUD | -28.85% |
| 2012 Q2 | 2.89 Million AUD | 80.88% |
| 2012 Q3 | 2.89 Million AUD | 0.0% |
| 2012 Q4 | 2.89 Million AUD | 0.0% |
| 2012 FY | - AUD | 48.33% |
| 2012 Q1 | 1.6 Million AUD | 0.0% |
| 2011 Q4 | 1.6 Million AUD | 0.0% |
| 2011 FY | - AUD | 15.18% |
| 2011 Q3 | 1.6 Million AUD | 0.0% |
| 2011 Q2 | 1.6 Million AUD | -26.33% |
| 2011 Q1 | 2.17 Million AUD | 0.0% |
| 2010 Q3 | 2.17 Million AUD | 0.0% |
| 2010 Q4 | 2.17 Million AUD | 0.0% |
| 2010 Q1 | -1.02 Million AUD | 0.0% |
| 2010 Q2 | 2.17 Million AUD | 312.15% |
| 2010 FY | - AUD | 279.46% |
| 2009 Q3 | -1.02 Million AUD | 0.0% |
| 2009 Q2 | -1.02 Million AUD | -18.78% |
| 2009 Q1 | -862.61 Thousand AUD | 0.0% |
| 2009 Q4 | -1.02 Million AUD | 0.0% |
| 2009 FY | - AUD | -18.78% |
| 2008 Q1 | -454.75 Thousand AUD | 0.0% |
| 2008 Q4 | -862.61 Thousand AUD | 0.0% |
| 2008 Q2 | -862.61 Thousand AUD | -89.69% |
| 2008 Q3 | -862.61 Thousand AUD | 0.0% |
| 2008 FY | - AUD | -90.4% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q4 | -454.75 Thousand AUD | 0.0% |
| 2007 Q3 | -454.75 Thousand AUD | 0.0% |
| 2007 Q2 | -454.75 Thousand AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Firebrick Pharma Limited | -1.08 Million AUD | -10679.62% |